BR112014012495A2 - método in vitro, kit, inibidor de egfr e método de tratamento de pacientes afetados com câncer - Google Patents
método in vitro, kit, inibidor de egfr e método de tratamento de pacientes afetados com câncerInfo
- Publication number
- BR112014012495A2 BR112014012495A2 BR112014012495A BR112014012495A BR112014012495A2 BR 112014012495 A2 BR112014012495 A2 BR 112014012495A2 BR 112014012495 A BR112014012495 A BR 112014012495A BR 112014012495 A BR112014012495 A BR 112014012495A BR 112014012495 A2 BR112014012495 A2 BR 112014012495A2
- Authority
- BR
- Brazil
- Prior art keywords
- kit
- treating cancer
- egfr inhibitor
- affected patients
- cancer affected
- Prior art date
Links
- 238000000034 method Methods 0.000 title 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 229940121647 egfr inhibitor Drugs 0.000 title 1
- 238000000338 in vitro Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11306568 | 2011-11-25 | ||
| EP12306042 | 2012-08-31 | ||
| PCT/EP2012/073535 WO2013076282A1 (en) | 2011-11-25 | 2012-11-23 | A method for predicting responsiveness to a treatment with an egfr inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014012495A2 true BR112014012495A2 (pt) | 2017-06-06 |
Family
ID=47297187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014012495A BR112014012495A2 (pt) | 2011-11-25 | 2012-11-23 | método in vitro, kit, inibidor de egfr e método de tratamento de pacientes afetados com câncer |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10400284B2 (https=) |
| EP (1) | EP2783017B1 (https=) |
| JP (1) | JP6342329B2 (https=) |
| KR (1) | KR20140104419A (https=) |
| CN (1) | CN104160038B (https=) |
| AU (1) | AU2012342397B2 (https=) |
| BR (1) | BR112014012495A2 (https=) |
| CA (1) | CA2856594A1 (https=) |
| MX (1) | MX2014006182A (https=) |
| WO (1) | WO2013076282A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015078906A1 (en) * | 2013-11-26 | 2015-06-04 | Integragen | A method for predicting responsiveness to a treatment with an egfr inhibitor |
| KR101622454B1 (ko) | 2014-03-04 | 2016-05-18 | 연세대학교 산학협력단 | Egfr 티로신 키나아제 억제제에 대한 항암 치료 반응 예측 마커 |
| EP3131552B1 (en) * | 2014-04-16 | 2020-07-15 | Signal Pharmaceuticals, LLC | Methods for treating cancer using tor kinase inhibitor combination therapy |
| EP3000895A1 (en) * | 2014-09-26 | 2016-03-30 | Integragen | A method for predicting responsiveness to a treatment with an EGFR inhibitor |
| WO2017014694A1 (en) * | 2015-07-23 | 2017-01-26 | National University Of Singapore | Wbp2 as a co-prognostic factor with her2 for stratification of patients for treatment |
| EP3450555B1 (en) * | 2016-04-28 | 2020-11-18 | Denka Company Limited | Method for determining tolerance of cancer cell to epidermal growth factor receptor inhibitor |
| US20220160871A1 (en) * | 2019-03-29 | 2022-05-26 | Rakuten Medical, Inc. | Methods for photoimmunotherapy and related biomarkers |
| KR102251864B1 (ko) * | 2019-10-18 | 2021-05-14 | 지니너스 주식회사 | miR-320c를 유효성분으로 포함하는 백금계 항암제에 대한 삼중음성유방암 환자의 약물 반응성 예측용 바이오마커 조성물 |
| CN111798918A (zh) * | 2020-05-28 | 2020-10-20 | 中山大学孙逸仙纪念医院 | 一种免疫治疗疗效预测的血肿瘤突变算法及其构建方法 |
| CN111863159B (zh) * | 2020-06-01 | 2022-02-25 | 中山大学孙逸仙纪念医院 | 一种肿瘤免疫治疗疗效预测的列线图模型的建立方法 |
| US20250171855A1 (en) * | 2022-03-01 | 2025-05-29 | Crown Bioscience (Suzhou) Inc. | Methods for determining cetuximab sensitivity in cancer patients |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100523216C (zh) | 2001-03-02 | 2009-08-05 | 匹兹堡大学 | Pcr方法 |
| RU2010120674A (ru) * | 2007-10-22 | 2011-11-27 | Шеринг Корпорейшн (US) | Полностью человеческие анти-vegf-антитела и способы их применения |
| WO2009080437A1 (en) * | 2007-12-21 | 2009-07-02 | Exiqon A/S | Micro-rna based drug resistance analysis method |
| WO2010015538A2 (en) * | 2008-08-05 | 2010-02-11 | F. Hoffmann-La Roche Ag | Predictive marker for egfr inhibitor treatment |
| EP2419522A4 (en) | 2009-04-17 | 2012-10-31 | Glen Weiss | METHOD AND KITS FOR THE FORECASTING OF THERAPY RESULTS OF TYROSINE CHINESE INHIBITORS |
| JP2013511559A (ja) * | 2009-11-24 | 2013-04-04 | ザ ユニバーシティ オブ ウェスタン オーストラリア | 上皮成長因子受容体リガンドのモジュレーション |
| CA2800557A1 (en) * | 2010-04-29 | 2011-11-03 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy |
-
2012
- 2012-11-23 JP JP2014542865A patent/JP6342329B2/ja not_active Expired - Fee Related
- 2012-11-23 EP EP12797814.6A patent/EP2783017B1/en not_active Not-in-force
- 2012-11-23 CN CN201280067832.4A patent/CN104160038B/zh not_active Expired - Fee Related
- 2012-11-23 AU AU2012342397A patent/AU2012342397B2/en not_active Ceased
- 2012-11-23 MX MX2014006182A patent/MX2014006182A/es unknown
- 2012-11-23 WO PCT/EP2012/073535 patent/WO2013076282A1/en not_active Ceased
- 2012-11-23 KR KR1020147014013A patent/KR20140104419A/ko not_active Ceased
- 2012-11-23 US US14/360,311 patent/US10400284B2/en not_active Expired - Fee Related
- 2012-11-23 BR BR112014012495A patent/BR112014012495A2/pt active Search and Examination
- 2012-11-23 CA CA2856594A patent/CA2856594A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US10400284B2 (en) | 2019-09-03 |
| AU2012342397B2 (en) | 2018-04-05 |
| EP2783017A1 (en) | 2014-10-01 |
| CA2856594A1 (en) | 2013-05-30 |
| CN104160038A (zh) | 2014-11-19 |
| JP2014533960A (ja) | 2014-12-18 |
| US20140370029A1 (en) | 2014-12-18 |
| EP2783017B1 (en) | 2018-12-26 |
| CN104160038B (zh) | 2018-06-12 |
| KR20140104419A (ko) | 2014-08-28 |
| JP6342329B2 (ja) | 2018-06-13 |
| WO2013076282A1 (en) | 2013-05-30 |
| MX2014006182A (es) | 2014-12-08 |
| AU2012342397A1 (en) | 2014-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014012495A2 (pt) | método in vitro, kit, inibidor de egfr e método de tratamento de pacientes afetados com câncer | |
| IL286921A (en) | Pertuzumab and trastuzumab for use in therapy | |
| HUE036583T2 (hu) | Notch jelzõ folyamat inhibitorai és alkalmazásuk rákok kezelésében | |
| SMT201600430B (it) | Inibitori di chinasi e loro uso nel trattamento del cancro | |
| IL217030A (en) | Biomarkers and methods for determining efficacy of anti-egfr antibodies in cancer therapy | |
| BR112014007603A2 (pt) | métodos de tratamento do câncer | |
| BR112014001440A2 (pt) | novas composições e métodos para o tratamento de câncer de próstata | |
| PL2552438T3 (pl) | Sposoby leczenia raka wątrobowokomórkowego | |
| HUE040445T2 (hu) | Antiszensz molekulák és eljárások betegségek kezelésére | |
| DK2473510T3 (da) | Jak-2-hæmmere og anvendelse heraf til behandling af myeloproliferativesygdomme og cancer | |
| BR112014009755A2 (pt) | tratamento de câncer com inibidores de quinase tor | |
| PT2434891T (pt) | Métodos para tratamento de cancro e afeções não neoplásicas | |
| IL232256A0 (en) | Novel purine derivatives and their use in the treatment of disease | |
| EP2665749A1 (en) | Anti - il1rap antibodies and their use for treating human | |
| BR112013012485A2 (pt) | método de tratamento com inibidor braf | |
| IL220788A (en) | Factors associated with cancer treatment and method of preparation | |
| BR112014004937A2 (pt) | método para tratar e/ou prevenir um câncer dependente de ligante de ahr natural e inibidor de ahr | |
| PT2528946T (pt) | Métodos de tratamento de doenças autoimunes com antagonistas de dll4 | |
| BR112014001973A2 (pt) | composto e método de tratamento do câncer em um sujeito | |
| IL226246A0 (en) | Methods of treating cancer | |
| HUE063599T2 (hu) | Eljárások ödémás fibroszklerotikus pannikulopátia kezelésére vagy csökkentésére | |
| PT2772486T (pt) | Inibidor de quinase e método para tratamento de doenças relacionadas | |
| BR112014011008A2 (pt) | método de quantificação de tratamento de câncer | |
| PL3400958T3 (pl) | Kompozycje i metody leczenia celiakii | |
| PL2742356T3 (pl) | Środki prognostyczne w leczeniu nowotworów |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08H | Application fees: decision cancelled [chapter 8.8 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 8.6 NA RPI NO 2541 DE 17/09/2019 POR TER SIDO INDEVIDA. |
|
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |